Updates in NOAC Reversal, What Have We Learned? is organized by Academy for Continued Healthcare Learning (ACHL).
Release Date: Aug 30, 2019
Expires on: Aug 30, 2020
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Dr. Gregory Piazza and Dr. Christian Ruff present recent clinical data, guideline recommendations and updates on navigating the use of newly approved and emerging NOAC reversal agents. This video commentary will include clinical case review and discussions about strategies to navigate the complexities of reversing the anticoagulant effects of NOACs across diverse patient populations in emergent medical situations.
After participating in this program, the participant should be able to:
• Review current approaches to the management of bleeding in patients receiving NOACs, as well as unmet needs with current practices
• Compare and contrast approved and emerging reversal agents for NOACs, including their mechanisms of action and available data
• Discuss clinical strategies for NOAC reversal in emergent patient scenarios
Additional details will be posted as soon as information is available.
This activity is intended for hospitalists, cardiologists, primary care physicians, nurses and others with an interest in NOAC reversal.